When a failed trial isn't a failed drug A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment. Written byBree Foster, PhD

When a failed trial isn't a failed drug A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment. Written byBree Foster, PhD https://www.drugdiscoverynews.com/when-a-failed-trial-isn-t-a-failed-drug-17431?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--mxkzU3Gubg4olGXThSyNhbwo1LkK8D-VbpIDPK_Ce-Gi1oNSKP3mkcGO4UioLOPx_pYHAYAoiRJuqkzK0VmbcE1DOrQ&_hsmi=443231356&utm_content=443231356&utm_source=hs_email When a Phase 3 clinical trial misses its primary endpoint, the outcome is often treated as definitive. The drug failed to demonstrate efficacy, development stops, and the therapy may never be tested again. But a negative trial in a heterogeneous patient population does not necessarily mean that every participant failed to benefit. It may instead mean that any treatment effect was diluted when patients with very different disease biology and treatment responses were analyzed together. That possibility has become increasingly important as drug development moves toward precision medicine. Many diseases once treated as single disorders are now understood to encompass biologically diverse patient populations. But pivotal Phase 3 trials are still generally designed to answer a binary question: does the drug work across the overall study population?